Pivotal assessment of the effects of bioactives on health and wellbeing - From human genoma to food industry (PATHWAY-27) has reached its midterm. The general objective of PATHWAY-27 addresses the exploitation of bioactive compounds as ingredients of foods that, within the common diet, could significantly benefit human health and wellbeing. PATHWAY-27 uses three model compounds (docosahexaenoic acid - DHA, beta-glucan - BG, and anthocyanins - AC) and three model food matrices (bakery, dairy and egg products) to derive conclusions that will be widely applicable.
The scientific objective of PATHWAY-27 is to better understand the potential benefits and mechanisms of action of the selected bioactive compounds (DHA, BG and AC), considered as ingredients of the PATHWAY-27 bioactive-enriched foods (BEF), in the prevention of the Metabolic Syndrome (MS).
PATHWAY (FP7-KBBE-2012-6-singlestage) is a collaborative project targeted to SMEs and financed by the EC under the FP7. PATHWAY-27 includes 25 partners broadly distributed in Europe: west to east, south to north Europe, including one Candidate Country (Turkey). VTT leads work package 4 with overall objective to extract and purify the selected bioactives from dietary sources, and to use them for the production of bioactive-enriched foods (BEF) for the pilot and intervention studies.
Download PATHWAY-27 leaflet to learn more about the midterm results and next steps:
For more information: